The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $36.5, a high estimate of $66.00, and a low estimate of $17.00. Experiencing a 18.74% decline, ...

CEO Dr. Ron Kurtz highlighted that Q1 2025 revenue was impacted by a weakened premium intraocular lens (IOL ... to highlight the benefits of RxSight’s adjustable IOL platform.

RxSight (NASDAQ:RXST), a maker of light-adjustable intraocular lenses, fell ~28% in the premarket after the company slashed its full-year guidance and announced lower-than-expected preliminary revenue ...

Sold 27,579 Light Adjustable Lenses (LALs), up 36% year-over-year. LDD installed base increased to 1,044 units, up 43% year-over-year. RxSight revised its 2025 revenue guidance to $160-175 million ...

RxSight projects the sale of 27,579 Light Adjustable Lenses (LAL/LAL+), with a growth of 36%Y/Y increase in procedure volume. Also, the company anticipates the sale of 73 Light Delivery Devices ...

The sale of 27,579 Light Adjustable Lenses (LAL™/LAL+ ®); representing a 36% increase in procedure volume compared to the first quarter of 2024; and The sale of 73 Light Delivery Devices (LDD ...

April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic ... The sale of 27,579 Light Adjustable Lenses (LAL™/LAL+ ®); representing a 36% increase in procedure volume ...